908 Devices (NASDAQ:MASS) Earns Sell (E+) Rating from Weiss Ratings

908 Devices (NASDAQ:MASS)‘s stock had its “sell (e+)” rating reaffirmed by equities researchers at Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

MASS has been the topic of a number of other reports. Leerink Partnrs downgraded 908 Devices from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 13th. Stephens restated an “overweight” rating and set a $6.00 price target on shares of 908 Devices in a research note on Wednesday, January 15th. Stifel Nicolaus lowered their price objective on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Finally, Leerink Partners restated a “market perform” rating and set a $4.00 target price (down from $12.00) on shares of 908 Devices in a research report on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.33.

908 Devices Stock Performance

Shares of NASDAQ MASS opened at $2.98 on Friday. The firm’s 50 day moving average price is $2.36 and its 200-day moving average price is $3.49. 908 Devices has a 52-week low of $1.81 and a 52-week high of $8.50. The company has a market cap of $103.76 million, a PE ratio of -1.68 and a beta of 0.96.

Hedge Funds Weigh In On 908 Devices

A number of institutional investors and hedge funds have recently made changes to their positions in MASS. Bank of New York Mellon Corp boosted its holdings in shares of 908 Devices by 6.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 69,550 shares of the company’s stock worth $358,000 after purchasing an additional 4,212 shares during the period. American Century Companies Inc. boosted its stake in 908 Devices by 18.6% during the second quarter. American Century Companies Inc. now owns 33,718 shares of the company’s stock worth $174,000 after buying an additional 5,295 shares during the period. Dimensional Fund Advisors LP increased its position in 908 Devices by 88.3% during the second quarter. Dimensional Fund Advisors LP now owns 245,176 shares of the company’s stock valued at $1,263,000 after acquiring an additional 114,987 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of 908 Devices by 79.4% in the second quarter. Renaissance Technologies LLC now owns 195,500 shares of the company’s stock valued at $1,007,000 after acquiring an additional 86,500 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of 908 Devices in the 2nd quarter worth about $229,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.